TABLE 2.
Incidence of post‐cannulation complications
| Event | Non‐COVID‐19 (n = 112; 1781 days) | COVID‐19 (n = 26; 756 days) | p value | ||||
|---|---|---|---|---|---|---|---|
| Patients | Events | EPPD | Patients | Events | EPPD | ||
| AKI | 48 (42.9%) | – | – | 14 (53.8%) | – | – | .17 |
| Dialysis | 36 (32.1%) | – | – | 9 (34.6%) | – | – | .82 |
| Tracheostomy | 63 (56.3%) | – | – | 18 (69.2%) | – | – | .22 |
| Neurological dysfunction | 6 (5.3%) | 6 | 0.003 | 0 (0%) | 0 | 0.000 | .19 |
| Oxygenator exchange | 37 (33%) | 41 | 0.021 | 11 (42.3%) | 11 | 0.056 | .37 |
| Sepsis | 16 (13.5%) | 18 | 0.009 | 5 (19.2%) | 6 | 0.031 | .75 |
| Bleeding complication | 61 (54.4%) | 68 | 0.034 | 12 (46.1%) | 15 | 0.076 | .03 |
| Hemothorax | 14 (12.5%) | 14 | 0.007 | 4 (15.3%) | 4 | 0.020 | <.001 |
| Oral/Nasal bleeding | 19 (16.9%) | 19 | 0.010 | 7 (26.9%) | 7 | 0.036 | .04 |
| GI bleeding | 15 (13.3%) | 18 | 0.009 | 3 (11.5%) | 3 | 0.015 | .34 |
| HND | 4 (3.5%) | 4 | 0.002 | 1 (3.4%) | 1 | 0.005 | .94 |
| DAH | 11 (9.8%) | 11 | 0.006 | 0 (0%) | 0 | 0.000 | .09 |
| Retroperitoneal bleeding | 2 (1.7%) | 2 | 0.001 | 0 (0%) | 0 | 0.000 | .49 |
| Thrombotic complications | 27 (24.1%) | 30 | 0.015 | 12 (46.1%) | 13 | 0.066 | <.001 |
| DVT | 21 (18.7%) | 21 | 0.011 | 12 (46.1%) | 12 | 0.061 | <.001 |
| PE | 2 (1.7%) | 2 | 0.001 | 0 (0%) | 0 | 0.000 | .49 |
| Ischemic fingers | 5 (4.4%) | 5 | 0.003 | 1 (3.4%) | 1 | 0.005 | .88 |
Abbreviations: AKI, acute kidney injury; DAH, diffuse alveolar hemorrhage; DVT, deep venous thrombosis; EPPD, event per patient‐day; GI bleeding; gastrointestinal bleeding; HND, hemorrhagic neurological dysfunction; IND, ischemic neurological dysfunction; PE, pulmonary embolism.